Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- PaO2/FiO2
研究概览
简要总结
Many questions about management of COVID-19 are still not answered. So, we recruit this study aiming to evaluate improvement of oxygenation in COVID-19 patients with severe ARDS, to improve morbidity and mortality of ICU covid patients, to participate in understanding of real hidden pathophysiology of COVID-19.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Severe ARDS: PaO2/FiO2 <200, resistant hypoxemia and tachypnoea (RR > 40 breath/minute)
- •Not relieved by high frequency nasal canula or CPAP.
- •Need for invasive mechanical ventilation (uncooperative)
排除标准
- •Patient relatives' refusal
- •Not mechanically ventilated.
- •Combination of female, corticosteroids administration and vecuronium muscle relaxant.
- •Neuromuscular diseases (especially demyelinating diseases).
研究组 & 干预措施
Muscle relaxant group(group B)
They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.
干预措施: muscle relaxation (Drug)
结局指标
主要结局
PaO2/FiO2
时间窗: 48 hours
ratio of arterial oxygen pressure in millilitre mercury to fraction of inspired oxygen at same time within the arterial blood gas
次要结局
- Change in lung mechanics(48 hours)
- SOFA score(48 hours)
- Measurement of tissue perfusion(48 hours)
- 28 days survival(after 28 days)
- Recording risk factors(28 days)
- Monitoring of Alveolar - Arterial Oxygen difference(48 hours)
- Recording complications(28 days)
研究者
Ayman Abd El-Khalek Mohammed Glala
Principle investigator
Assiut University